for eMaxHealthLas Vegas gynecologists now have access to a revolutionary non-invasive outpatient procedure that combines magnetic resonance imaging and focused ultrasound to destroy tumors (uterine fibroids).
One out of every three hysterectomies performed are due to benign tumors. Over 25 percent of women in the United States have clinically symptomatic uterine fibroids and as many as 77 percent of all women could have uterine fibroids and many do not even know it.
ExAblate of Las Vegas, the only facility in Nevada to offer this incisionless procedure, is now open at 7170 Smoke Ranch Road, Suite 110.
"The patients we have treated have returned to normal activities in one to two days. Other surgical treatments for fibroids are invasive and can require several days of hospital stay and up to six weeks of recovery time. The ExAblate technology combines magnetic resonance imaging and focused ultrasound, which enables us to not only see the fibroid and surrounding organs in 3D, but to destroy the targeted tumors inside the body without the need for traditional surgical incisions," said Dr. Sheldon Paul, medical director for ExAblate of Las Vegas.
The ExAblate treatment offers women with symptomatic uterine fibroids the only non-invasive alternative to surgical treatment options such as hysterectomy, myomectomy, and uterine artery embolization (UAE). Hysterectomy, the full removal of the uterus, can lead to complications associated with major surgery and will send the patient into early menopause. The procedure requires two to five days of hospitalization and six to eight weeks of recovery. Myomectomy, the surgical removal of he fibroid, and UAE both require hospitalization and lengthy recovery time. With ExAblate, the patient goes home the same day of the procedure and can return to normal activities within two days.
Over 3,000 patients worldwide have already benefited from The ExAblate treatment which is the only U.S. Food and Drug Administration (FDA) - approved system to use the breakthrough MR-guided Focused Ultrasound (MRgFUS) technology that combines MRI -- to visualize tissues in the body, plan the treatment and monitor, in real time, treatment outcome -- and high intensity focused ultrasound to thermally ablate tissue. MR thermal feedback, provided uniquely by the system, allows the physician to control and adjust the treatment in real time to ensure that the targeted tumor is fully treated and surrounding tissue is spared. ExAblate received FDA approval for the treatment of symptomatic uterine fibroids in October 2004.
ExAblate of Las Vegas is a joint venture between local physicians and Deployed Medical Solutions Inc., a Houston, Texas based company dedicated to providing patients and gynecologists access to this revolutionary new technology. Deployed Medical Solutions owns and operates six facilities across the country.
"We are pleased that we will be able to offer gynecologists and the women of Nevada access to this new, non-invasive treatment for a condition that has previously only been treated with invasive surgery," said Charles Cohen, president and chief executive officer of Deployed Medical Solutions, Inc.
eMaxHealth welcomes yourcomments and feedback on this story without registration, but keep the comments meaningful please. Links are not accepted.
